Quantcast
Last updated on April 18, 2014 at 6:03 EDT

Latest Novartis AG Stories

2011-12-12 16:51:00

EAST HANOVER, N.J., Dec. 12, 2011 /PRNewswire/ -- Phase III clinical trial data presented today contribute to the growing evidence that adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase who are treated with Tasigna® (nilotinib) have deeper levels of response compared to those treated with Gleevec® (imatinib mesylate) tablets(*1,2). The findings from the ENEST (Evaluating...

2011-12-07 17:34:00

EAST HANOVER, N.J., Dec. 7, 2011 /PRNewswire/ -- Updated results of a Phase III study of Afinitor® (everolimus) tablets plus exemestane, a hormonal therapy, show everolimus provided additional time women with advanced breast cancer lived without their disease progressing (progression-free survival)(1). The study findings, which represent an additional five months of follow-up, were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium...

2011-11-18 00:20:01

Tokyo, Nov 18, 2011 - (JCN Newswire) - Eisai Co. Ltd announced today that it has entered into a Japan co-promotion agreement with Novartis Pharma K.K. for three Novartis Pharma therapies for chronic obstructive pulmonary disease (COPD). These include Onbrez Inhalation Capsules 150 mcg (indacaterol maleate), which were launched in Japan on September 20, 2011, and, if approved, the investigational drugs NVA237 (glycopyrronium bromide) and QVA149 (fixed-dose combination of indacaterol maleate...

2011-11-10 15:10:00

PARSIPPANY, N.J., Nov. 10, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rivastigmine transdermal system patches, 4.6 mg/24 hr and 9.5 mg/24 hr. Watson's rivastigmine transdermal system patch is a generic version of Novartis' Exelon(R) Patch. Exelon(R) is a prescription medicine used to...

2011-11-07 00:15:00

EAST HANOVER, N.J., Nov. 7, 2011 /PRNewswire/ -- Novartis announced today new pivotal Phase III data showing 45% of children with active systemic juvenile idiopathic arthritis (SJIA) were able to substantially reduce their use of oral corticosteroids (often described as steroids) within 28 weeks of commencing treatment with ACZ885 (canakinumab) (p<0.0001)[1]. The results of the study, which met both primary endpoints, will be presented on November 9th at the...

2011-09-25 17:07:00

EAST HANOVER, N.J., Sept. 25, 2011 /PRNewswire/ -- A pivotal Phase III study shows Afinitor® (everolimus) tablets plus exemestane, a hormonal therapy, more than doubled the time women lived without tumor growth (progression-free survival; PFS) and significantly reduced the risk of cancer progression by 57% versus exemestane alone in patients with advanced breast cancer(1). "Everolimus is the first drug to show significant efficacy when combined with hormonal therapy in...

2011-09-23 10:33:00

EAST HANOVER, N.J., Sept. 23, 2011 /PRNewswire/ -- A Phase III study of Afinitor® (everolimus) tablets* in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors. Findings from the trial, known as EXIST-2, were presented today at the International TSC Research Conference...

2011-09-16 10:45:00

EAST HANOVER, N.J., Sept. 16, 2011 /PRNewswire/ -- Novartis announced today positive results of the first pivotal Phase III trial of ACZ885 in patients with systemic juvenile idiopathic arthritis (SJIA), a rare and serious childhood auto-inflammatory disease[3]. The results, presented at the 2011 European Pediatric Rheumatology Congress in Bruges, Belgium, showed all primary and secondary endpoints of the study were met[2]. Most ACZ885 patients (83.7%) experienced at least a 30%...

2011-09-07 08:31:00

CHICAGO, Sept. 7, 2011 /PRNewswire/ -- Seven Summits Research issues critical PriceWatch Alerts for VZ, CVS, ECA, NVS, and WU. To see what our analysts have discovered about these stocks read the Seven Summits Strategic Investments' PriceWatch Alerts at http://www.iotogo.com/s/090711B (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's PriceWatch Alerts cover the following stocks: Verizon Communications Inc. (NYSE: VZ), CVS Caremark Corporation...

2011-09-01 08:30:00

CHICAGO, Sept. 1, 2011 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Gap Inc. (NYSE: GPS), Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA), Novartis AG (NYSE: NVS), Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) and Mylan Inc. (Nasdaq: MYL). (Logo:...